Hematopoietic/Lymphoid Cancer Withdrawn Phase 2 Trials for Lenalidomide (DB00480)

IndicationStatusPhase
DBCOND0030132 (Hematopoietic/Lymphoid Cancer)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03232307Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaTreatment